Abstract
The authors quantitated CSF levels of nerve growth factor (NGF) in patients with AD, nondemented control subjects (CTR), and age-matched patients with major depression (DE). CSF levels of NGF were markedly higher in the AD group than in both the CTR and DE groups (p < 0.01 and p < 0.001). Increased CSF levels of NGF in AD patients may reflect reported accumulation of NGF in the AD brain and may constitute a candidate marker for clinical diagnosis and therapeutic monitoring.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Alzheimer Disease / cerebrospinal fluid
-
Alzheimer Disease / diagnosis*
-
Biomarkers / cerebrospinal fluid*
-
Depressive Disorder, Major / cerebrospinal fluid
-
Depressive Disorder, Major / diagnosis
-
Diagnosis, Differential
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nerve Growth Factor / cerebrospinal fluid*
-
Predictive Value of Tests
Substances
-
Biomarkers
-
Nerve Growth Factor